AI Terminal
Ascelia Pharma
Declaration of Voting Results & Voting Rights Announcements • Mar 31, 2022
3132_rns_2022-03-31_1729c841-4bd8-42e6-a907-dcf0a7cebdcf.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
31 March 2022 10:20:00 CEST
Number of shares and votes in Ascelia Pharma AB
During the month of March, the number of shares and votes in Ascelia Pharma AB have increased due to directed issue and repurchase of 294,729 series C shares, which were resolved upon by the board of directors on 2 March 2022 pursuant to the authorization granted by the annual general meeting on 5 May 2021.
As of 31 March 2022, the number of shares in Ascelia Pharma AB amounts to 34,871,177 shares, of which 33,668,262 are ordinary shares with one vote per share and 1,202,915 are series C shares with one-tenth of a vote per share. The number of votes in the company amounts to 33,788,553.5 votes.
Contacts
Magnus Corfitzen, CEO Email: [email protected] Tel: 46 735 179 118
Mikael Widell, IR & Communications Email: [email protected] Tel: +46 703 11 99 60
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-03-31 10:20 CEST.
About Us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
About Orviglance (previously referred to as Mangoral)
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.
About Oncoral
Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.